Quest Diagnostics DGX is set to release its first-quarter 2025 results on April 22, before the market opens. The renowned ...

This was the stock's second consecutive day of losses.

BofA analyst Michael Ryskin raised the firm’s price target on Quest Diagnostics (DGX) to $198 from $190 and keeps a Buy rating on the shares.

There was a mix-up regarding my appointment for blood testing this morning. I arrived on time for my appointment but the kiosk indicated no appointment scheduled. It was 10 minutes to 12 (office ...

Mizuho raised the firm’s price target on Quest Diagnostics (DGX) to $189 from $178 and keeps an Outperform rating on the shares. The firm ...

Quest Diagnostics (NYSE:DGX) recently introduced the AD-Detect™ blood test, a significant development aimed at confirming Alzheimer's-related amyloid brain pathology. Over the last quarter ...

Quest Diagnostics Incorporated has a 52 week low of $125.42 and a 52 week high of $178.87. The company has a quick ratio of 1.02, a current ratio of 1.10 and a debt-to-equity ratio of 0.82.

This week, Quest Diagnostics made one of those deals. The diagnostics giant announced a new partnership with Google Cloud that aims to deliver new AI capabilities — including predictive ...

Shares of Quest Diagnostics Inc. DGX slid 2.74% to $159.80 Tuesday, on what proved to be an all-around dismal trading session ...

Quest Diagnostics Inc.’s DGX investments in Advanced Diagnostics are paying off, aiming to deliver and scale innovative services that improve patient care and drive growth. The company focuses ...